vertical pharma resources limited
vertical pharma resources limited Company Information
Company Number
06077026
Next Accounts
Nov 2025
Shareholders
integrated pharmaceutical services (ips) ltd
Group Structure
View All
Industry
Manufacture of pharmaceutical preparations
Registered Address
41 central avenue, west molessey, surrey, KT8 2QZ
Website
http://vprpharmacy.comvertical pharma resources limited Estimated Valuation
Pomanda estimates the enterprise value of VERTICAL PHARMA RESOURCES LIMITED at £45.4m based on a Turnover of £23.6m and 1.93x industry multiple (adjusted for size and gross margin).
vertical pharma resources limited Estimated Valuation
Pomanda estimates the enterprise value of VERTICAL PHARMA RESOURCES LIMITED at £15.5m based on an EBITDA of £1.9m and a 8.35x industry multiple (adjusted for size and gross margin).
vertical pharma resources limited Estimated Valuation
Pomanda estimates the enterprise value of VERTICAL PHARMA RESOURCES LIMITED at £6.8m based on Net Assets of £3.5m and 1.95x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Vertical Pharma Resources Limited Overview
Vertical Pharma Resources Limited is a live company located in surrey, KT8 2QZ with a Companies House number of 06077026. It operates in the manufacture of pharmaceutical preparations sector, SIC Code 21200. Founded in February 2007, it's largest shareholder is integrated pharmaceutical services (ips) ltd with a 100% stake. Vertical Pharma Resources Limited is a established, large sized company, Pomanda has estimated its turnover at £23.6m with rapid growth in recent years.
Upgrade for unlimited company reports & a free credit check
Vertical Pharma Resources Limited Health Check
Pomanda's financial health check has awarded Vertical Pharma Resources Limited a 4.5 rating. We use a traffic light system to show it exceeds the industry average on 5 measures and has 4 areas for improvement. Company Health Check FAQs
5 Strong
3 Regular
4 Weak
Size
annual sales of £23.6m, make it smaller than the average company (£32.8m)
£23.6m - Vertical Pharma Resources Limited
£32.8m - Industry AVG
Growth
3 year (CAGR) sales growth of 36%, show it is growing at a faster rate (5.6%)
36% - Vertical Pharma Resources Limited
5.6% - Industry AVG
Production
with a gross margin of 31%, this company has a comparable cost of product (32.9%)
31% - Vertical Pharma Resources Limited
32.9% - Industry AVG
Profitability
an operating margin of 7.4% make it as profitable than the average company (9%)
7.4% - Vertical Pharma Resources Limited
9% - Industry AVG
Employees
with 79 employees, this is similar to the industry average (93)
79 - Vertical Pharma Resources Limited
93 - Industry AVG
Pay Structure
on an average salary of £47.3k, the company has a lower pay structure (£65.7k)
£47.3k - Vertical Pharma Resources Limited
£65.7k - Industry AVG
Efficiency
resulting in sales per employee of £298.5k, this is less efficient (£373.3k)
£298.5k - Vertical Pharma Resources Limited
£373.3k - Industry AVG
Debtor Days
it gets paid by customers after 72 days, this is later than average (54 days)
72 days - Vertical Pharma Resources Limited
54 days - Industry AVG
Creditor Days
its suppliers are paid after 70 days, this is slower than average (35 days)
70 days - Vertical Pharma Resources Limited
35 days - Industry AVG
Stock Days
it holds stock equivalent to 38 days, this is less than average (114 days)
38 days - Vertical Pharma Resources Limited
114 days - Industry AVG
Cash Balance
has cash to cover current liabilities for 10 weeks, this is more cash available to meet short term requirements (8 weeks)
10 weeks - Vertical Pharma Resources Limited
8 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 65.9%, this is a higher level of debt than the average (44%)
65.9% - Vertical Pharma Resources Limited
44% - Industry AVG
VERTICAL PHARMA RESOURCES LIMITED financials
Vertical Pharma Resources Limited's latest turnover from February 2024 is £23.6 million and the company has net assets of £3.5 million. According to their latest financial statements, Vertical Pharma Resources Limited has 79 employees and maintains cash reserves of £1.4 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Feb 2024 | Feb 2023 | Feb 2022 | Feb 2021 | Feb 2020 | Feb 2019 | Feb 2018 | Feb 2017 | Feb 2016 | Feb 2015 | Feb 2014 | Feb 2013 | Feb 2012 | Feb 2011 | Feb 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 23,582,620 | 17,170,756 | 16,338,797 | 9,317,000 | 10,411,000 | 5,585,000 | 9,111,000 | 9,574,000 | 9,849,000 | 10,326,000 | 9,962,685 | 8,041,169 | 7,917,032 | 8,362,082 | 7,632,731 |
| Other Income Or Grants | |||||||||||||||
| Cost Of Sales | 16,272,734 | 11,517,509 | 10,569,320 | 5,836,000 | 6,434,000 | 2,668,000 | 4,397,000 | 3,887,000 | 3,779,000 | 3,569,000 | 2,759,330 | 2,147,891 | 1,458,227 | 1,084,776 | 812,840 |
| Gross Profit | 7,309,886 | 5,653,247 | 5,769,477 | 3,481,000 | 3,977,000 | 2,917,000 | 4,714,000 | 5,687,000 | 6,070,000 | 6,757,000 | 7,203,355 | 5,893,278 | 6,458,805 | 7,277,306 | 6,819,891 |
| Admin Expenses | 5,566,475 | 5,345,860 | 4,701,781 | 3,629,000 | 4,513,000 | 4,336,000 | 4,464,000 | 4,279,000 | 4,139,000 | 3,898,000 | 3,095,980 | 2,638,435 | 2,350,461 | 1,806,045 | 2,347,357 |
| Operating Profit | 1,743,411 | 307,387 | 1,067,696 | -148,000 | -536,000 | -1,419,000 | 250,000 | 1,408,000 | 1,931,000 | 2,859,000 | 4,107,375 | 3,254,843 | 4,108,344 | 5,471,261 | 4,472,534 |
| Interest Payable | 201 | 2,650 | 2,000 | 1,000 | 45 | 39 | 4,351 | 1,254 | |||||||
| Interest Receivable | 1,000 | 3,402 | 4,907 | ||||||||||||
| Pre-Tax Profit | 1,826,668 | -98,729 | 1,308,639 | -148,000 | -538,000 | -1,420,000 | 250,000 | 1,409,000 | 1,931,000 | 2,859,000 | 4,107,375 | 3,254,798 | 4,108,305 | 5,470,312 | 4,812,756 |
| Tax | 14,966 | 105,418 | 8,000 | -18,000 | 32,000 | 40,000 | 23,000 | 141,000 | 24,000 | -283,000 | -683,248 | -508,355 | -826,335 | -1,263,421 | -1,257,103 |
| Profit After Tax | 1,841,634 | 6,689 | 1,316,639 | -166,000 | -506,000 | -1,380,000 | 273,000 | 1,550,000 | 1,955,000 | 2,576,000 | 3,424,127 | 2,746,443 | 3,281,970 | 4,206,891 | 3,555,653 |
| Dividends Paid | 19,411,000 | 1,800,000 | |||||||||||||
| Retained Profit | 1,841,634 | 6,689 | 1,316,639 | -166,000 | -506,000 | -1,380,000 | -19,138,000 | 1,550,000 | 1,955,000 | 2,576,000 | 3,424,127 | 2,746,443 | 3,281,970 | 4,206,891 | 1,755,653 |
| Employee Costs | 3,734,571 | 3,622,545 | 3,317,222 | 2,506,000 | 2,380,000 | 2,471,000 | 2,314,000 | 1,848,943 | 1,620,916 | 1,383,804 | 1,121,503 | 1,843,221 | |||
| Number Of Employees | 79 | 77 | 79 | 77 | 76 | 59 | 72 | 76 | 69 | 56 | 48 | 41 | 36 | 26 | 22 |
| EBITDA* | 1,856,871 | 407,708 | 1,171,610 | -21,000 | -290,000 | -1,055,000 | 662,000 | 1,841,000 | 2,417,000 | 3,134,000 | 4,269,423 | 3,388,643 | 4,114,245 | 5,499,502 | 4,487,423 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Feb 2024 | Feb 2023 | Feb 2022 | Feb 2021 | Feb 2020 | Feb 2019 | Feb 2018 | Feb 2017 | Feb 2016 | Feb 2015 | Feb 2014 | Feb 2013 | Feb 2012 | Feb 2011 | Feb 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 221,671 | 191,537 | 103,563 | 170,000 | 165,000 | 331,000 | 605,000 | 891,000 | 1,162,000 | 1,211,000 | 534,604 | 558,930 | 605,667 | 355,205 | 177,945 |
| Intangible Assets | 64,350 | 66,782 | 92,726 | 58,000 | 70,000 | 67,000 | 94,000 | 157,000 | 276,000 | 359,000 | |||||
| Investments & Other | 60,006 | 60,006 | 60,006 | ||||||||||||
| Debtors (Due After 1 year) | 144,150 | 129,184 | 94,000 | 60,000 | |||||||||||
| Total Fixed Assets | 490,177 | 447,509 | 350,295 | 288,000 | 235,000 | 398,000 | 699,000 | 1,048,000 | 1,438,000 | 1,570,000 | 534,604 | 558,930 | 605,667 | 355,205 | 177,945 |
| Stock & work in progress | 1,721,290 | 1,778,650 | 1,031,768 | 665,000 | 886,000 | 540,000 | 715,000 | 582,000 | 491,000 | 549,000 | 427,179 | 392,587 | 320,220 | 263,602 | 248,107 |
| Trade Debtors | 4,655,788 | 2,690,357 | 3,894,900 | 2,662,000 | 3,153,000 | 2,138,000 | 2,086,000 | 2,466,000 | 2,780,000 | 2,430,000 | 3,266,434 | 3,001,285 | 2,843,040 | 2,514,392 | 2,465,853 |
| Group Debtors | 18,055,000 | 16,564,000 | 15,262,000 | 11,832,583 | 13,440,261 | 10,391,946 | 4,582,537 | ||||||||
| Misc Debtors | 1,995,235 | 941,602 | 257,460 | 239,000 | 272,000 | 239,000 | 145,000 | 145,000 | 203,000 | 286,000 | 101,059 | 50,003 | 53,282 | 54,909 | 186,029 |
| Cash | 1,377,597 | 645,845 | 942,616 | 1,872,000 | 550,000 | 732,000 | 1,041,000 | 2,135,000 | 1,347,000 | 1,016,000 | 2,471,833 | 1,154,291 | 1,212,983 | 3,951,125 | 4,745,825 |
| misc current assets | |||||||||||||||
| total current assets | 9,749,910 | 6,056,454 | 6,126,744 | 5,438,000 | 4,861,000 | 3,649,000 | 3,987,000 | 23,383,000 | 21,385,000 | 19,543,000 | 18,099,088 | 18,038,427 | 14,821,471 | 11,366,565 | 7,645,814 |
| total assets | 10,240,087 | 6,503,963 | 6,477,039 | 5,726,000 | 5,096,000 | 4,047,000 | 4,686,000 | 24,431,000 | 22,823,000 | 21,113,000 | 18,633,692 | 18,597,357 | 15,427,138 | 11,721,770 | 7,823,759 |
| Bank overdraft | 3,006 | ||||||||||||||
| Bank loan | |||||||||||||||
| Trade Creditors | 3,155,504 | 1,605,331 | 1,254,563 | 3,343,000 | 2,866,000 | 1,371,000 | 1,686,000 | 2,199,000 | 2,104,000 | 2,418,000 | 2,121,066 | 1,737,510 | 1,300,861 | 990,407 | 995,358 |
| Group/Directors Accounts | 700,115 | 700,115 | 700,115 | 700,000 | 700,000 | 700,000 | 100 | ||||||||
| other short term finances | |||||||||||||||
| hp & lease commitments | |||||||||||||||
| other current liabilities | 2,889,230 | 2,544,913 | 2,875,446 | 1,353,000 | 1,034,000 | 974,000 | 618,000 | 712,000 | 653,000 | 560,000 | 1,028,812 | 812,858 | 809,735 | 723,886 | 1,048,990 |
| total current liabilities | 6,744,849 | 4,850,359 | 4,830,124 | 5,396,000 | 4,600,000 | 3,045,000 | 2,304,000 | 2,911,000 | 2,757,000 | 2,978,000 | 3,149,878 | 2,550,368 | 2,113,602 | 1,714,293 | 2,044,448 |
| loans | |||||||||||||||
| hp & lease commitments | |||||||||||||||
| Accruals and Deferred Income | |||||||||||||||
| other liabilities | |||||||||||||||
| provisions | 96,000 | 120,000 | 45,072 | 32,374 | 45,364 | 21,275 | |||||||||
| total long term liabilities | 96,000 | 120,000 | 45,072 | 32,374 | 45,364 | 21,275 | |||||||||
| total liabilities | 6,744,849 | 4,850,359 | 4,830,124 | 5,396,000 | 4,600,000 | 3,045,000 | 2,304,000 | 2,911,000 | 2,853,000 | 3,098,000 | 3,194,950 | 2,582,742 | 2,158,966 | 1,735,568 | 2,044,448 |
| net assets | 3,495,238 | 1,653,604 | 1,646,915 | 330,000 | 496,000 | 1,002,000 | 2,382,000 | 21,520,000 | 19,970,000 | 18,015,000 | 15,438,742 | 16,014,615 | 13,268,172 | 9,986,202 | 5,779,311 |
| total shareholders funds | 3,495,238 | 1,653,604 | 1,646,915 | 330,000 | 496,000 | 1,002,000 | 2,382,000 | 21,520,000 | 19,970,000 | 18,015,000 | 15,438,742 | 16,014,615 | 13,268,172 | 9,986,202 | 5,779,311 |
| Feb 2024 | Feb 2023 | Feb 2022 | Feb 2021 | Feb 2020 | Feb 2019 | Feb 2018 | Feb 2017 | Feb 2016 | Feb 2015 | Feb 2014 | Feb 2013 | Feb 2012 | Feb 2011 | Feb 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||
| Operating Profit | 1,743,411 | 307,387 | 1,067,696 | -148,000 | -536,000 | -1,419,000 | 250,000 | 1,408,000 | 1,931,000 | 2,859,000 | 4,107,375 | 3,254,843 | 4,108,344 | 5,471,261 | 4,472,534 |
| Depreciation | 79,455 | 69,054 | 81,720 | 82,000 | 215,000 | 323,000 | 337,000 | 294,000 | 296,000 | 275,000 | 162,048 | 133,800 | 5,901 | 28,241 | 14,889 |
| Amortisation | 34,005 | 31,267 | 22,194 | 45,000 | 31,000 | 41,000 | 75,000 | 139,000 | 190,000 | ||||||
| Tax | 14,966 | 105,418 | 8,000 | -18,000 | 32,000 | 40,000 | 23,000 | 141,000 | 24,000 | -283,000 | -683,248 | -508,355 | -826,335 | -1,263,421 | -1,257,103 |
| Stock | -57,360 | 746,882 | 366,768 | -221,000 | 346,000 | -175,000 | 133,000 | 91,000 | -58,000 | 121,821 | 34,592 | 72,367 | 56,618 | 15,495 | 248,107 |
| Debtors | 3,034,030 | -485,217 | 1,285,360 | -464,000 | 1,048,000 | 146,000 | -18,435,000 | 1,119,000 | 1,569,000 | 2,777,924 | -1,291,473 | 3,203,281 | 6,136,430 | 4,499,956 | 2,651,882 |
| Creditors | 1,550,173 | 350,768 | -2,088,437 | 477,000 | 1,495,000 | -315,000 | -513,000 | 95,000 | -314,000 | 296,934 | 383,556 | 436,649 | 310,454 | -4,951 | 995,358 |
| Accruals and Deferred Income | 344,317 | -330,533 | 1,522,446 | 319,000 | 60,000 | 356,000 | -94,000 | 59,000 | 93,000 | -468,812 | 215,954 | 3,123 | 85,849 | -325,104 | 1,048,990 |
| Deferred Taxes & Provisions | -96,000 | -24,000 | 74,928 | 12,698 | -12,990 | 24,089 | 21,275 | ||||||||
| Cash flow from operations | 789,657 | 271,696 | -1,038,509 | 1,442,000 | -97,000 | -945,000 | 18,380,000 | 830,000 | 685,000 | -145,695 | 5,455,264 | 31,422 | -2,484,746 | -588,150 | 2,374,679 |
| Investing Activities | |||||||||||||||
| capital expenditure | -33,744 | ||||||||||||||
| Change in Investments | 60,006 | ||||||||||||||
| cash flow from investments | -33,744 | ||||||||||||||
| Financing Activities | |||||||||||||||
| Bank loans | |||||||||||||||
| Group/Directors Accounts | 115 | 700,000 | -100 | 100 | |||||||||||
| Other Short Term Loans | |||||||||||||||
| Long term loans | |||||||||||||||
| Hire Purchase and Lease Commitments | |||||||||||||||
| other long term liabilities | |||||||||||||||
| share issue | |||||||||||||||
| interest | -201 | -2,650 | -2,000 | -1,000 | 1,000 | -45 | -39 | -949 | 3,653 | ||||||
| cash flow from financing | -201 | -2,259 | -2,000 | 699,000 | 1,000 | 258 | -4,000,000 | -45 | -39 | -1,049 | 4,027,411 | ||||
| cash and cash equivalents | |||||||||||||||
| cash | 731,752 | -296,771 | -929,384 | 1,322,000 | -182,000 | -309,000 | -1,094,000 | 788,000 | 331,000 | -1,455,833 | 1,317,542 | -58,692 | -2,738,142 | -794,700 | 4,745,825 |
| overdraft | -3,006 | 3,006 | |||||||||||||
| change in cash | 731,752 | -296,771 | -929,384 | 1,322,000 | -182,000 | -309,000 | -1,094,000 | 788,000 | 331,000 | -1,455,833 | 1,317,542 | -55,686 | -2,741,148 | -794,700 | 4,745,825 |
vertical pharma resources limited Credit Report and Business Information
Vertical Pharma Resources Limited Competitor Analysis
Perform a competitor analysis for vertical pharma resources limited by selecting its closest rivals, whether from the MANUFACTURING sector, other large companies, companies in KT8 area or any other competitors across 12 key performance metrics.
vertical pharma resources limited Ownership
VERTICAL PHARMA RESOURCES LIMITED group structure
Vertical Pharma Resources Limited has no subsidiary companies.
Ultimate parent company
2 parents
VERTICAL PHARMA RESOURCES LIMITED
06077026
vertical pharma resources limited directors
Vertical Pharma Resources Limited currently has 4 directors. The longest serving directors include Mr Ashokkumar Patel (Feb 2007) and Mr Vishal Patani (Sep 2018).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Ashokkumar Patel | United Kingdom | 69 years | Feb 2007 | - | Director |
| Mr Vishal Patani | England | 47 years | Sep 2018 | - | Director |
| Mr Soimitra Dutta | England | 62 years | Sep 2018 | - | Director |
| Dr James Parker | 69 years | May 2019 | - | Director |
P&L
February 2024turnover
23.6m
+37%
operating profit
1.7m
+467%
gross margin
31%
-5.85%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
February 2024net assets
3.5m
+1.11%
total assets
10.2m
+0.57%
cash
1.4m
+1.13%
net assets
Total assets minus all liabilities
vertical pharma resources limited company details
company number
06077026
Type
Private limited with Share Capital
industry
21200 - Manufacture of pharmaceutical preparations
incorporation date
February 2007
age
18
incorporated
UK
ultimate parent company
accounts
Full Accounts
last accounts submitted
February 2024
previous names
N/A
accountant
-
auditor
GERALD EDELMAN LLP
address
41 central avenue, west molessey, surrey, KT8 2QZ
Bank
CLYDESDALE BANK
Legal Advisor
-
vertical pharma resources limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to vertical pharma resources limited.
vertical pharma resources limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for VERTICAL PHARMA RESOURCES LIMITED. This can take several minutes, an email will notify you when this has completed.
vertical pharma resources limited Companies House Filings - See Documents
| date | description | view/download |
|---|
